Home › Non-Small Cell Lung Cancer › North Carolina › Durham
Non-Small Cell Lung Cancer clinical trials in Durham, NC
42 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Durham (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
RecruitingPhase 3
- Duke University Medical Center Duke Cancer Center, Durham
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
RecruitingPhase 1/2
- Duke Cancer Center Durham, Durham
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
RecruitingPhase 2
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi away
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RecruitingPhase 3
- Durham VA Medical Center, Durham
- Duke University Medical Center, Durham
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecruitingPhase 3
- Duke University Medical Center, Durham
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
RecruitingPhase 1
- Duke University Medical Center, Durham
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
RecruitingPhase 3
- UNC Lineberger Comprehensive Cancer Center ( Site 3250), Chapel Hill · 10 mi away
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
RecruitingPhase 1/2
- Duke Cancer Institute, Durham
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- Duke Cancer Institute, Durham
- University of North Carolina Medical Center, Chapel Hill · 10 mi away
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
RecruitingPhase 1
- Duke Health - Duke University Hospital, Durham
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
RecruitingPhase 2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi away
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
RecruitingPhase 2
- UNC Health - University of North Carolina, Chapel Hill · 10 mi away
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
RecruitingPhase 3
- Durham VA Health Care System, Durham
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RecruitingPhase 2/3
- Duke University Medical Center, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
RecruitingPhase 1
- Research Site, Durham
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Recruiting
- Durham VA Medical Center, Durham, NC, Durham
TOP 2301: Neoadjuvant Chemo for NSCLC
RecruitingPhase 2
- Duke University, Durham
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
RecruitingPhase 1/2
- Duke University School of Medicine, Durham
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
RecruitingPhase 3
- Duke University, Durham
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
RecruitingPhase 3
- Durham Veterans Affairs Health Care System, Durham
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
RecruitingPhase 1/2
- Duke Cancer Institute, Durham
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2/3
- Durham VA Medical Center, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- Duke University, Durham
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #12, Durham
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
RecruitingPhase 3
- Duke Cancer Center, Durham
A Study of PHN-012 in Patients With Advanced Solid Tumors
RecruitingPhase 1
- PHN-012-001 Site, Durham
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RecruitingPhase 3
- Clinical Study Site, Durham
- Clinical Study Site, Chapel Hill · 10 mi away
Effects of Infusion Timing on Treatment Response in Solid Tumors
RecruitingPhase 2
- University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill · 10 mi away
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RecruitingObservational study
- UNC- Chapel Hill, Chapel Hill · 10 mi away
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RecruitingPhase 1
- Duke Cancer Institute, Durham
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
RecruitingPhase 1
- University of North Carolina - Gastroenterology and Hepatology, Chapel Hill · 10 mi away
- University of North Carolina, Chapel Hill · 10 mi away
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Duke Cancer Center, Durham
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
RecruitingPhase 2
- University of North Carolina, Chapel Hill · 10 mi away
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RecruitingPhase 1
- Duke Cancer Institute /ID# 276267, Durham
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Research Site, Durham
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
RecruitingPhase 1
- Duke Cancer Center /ID# 251975, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RecruitingPhase 1
- Duke Cancer Center, Durham
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RecruitingPhase 2
- Durham VA Medical Center, Durham
GEMINI-NSCLC: NSCLC Biomarker Study
RecruitingObservational study
- Duke University, Durham
- UNC, Chapel Hill · 10 mi away
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi away
A Study of NX-1607 in Adults With Advanced Malignancies
RecruitingPhase 1
- University of North Carolina, Chapel Hill · 10 mi away
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX143 studies
- New York City, NY123 studies
- Arlington, VA111 studies
- Nashville, TN97 studies
- Los Angeles, CA92 studies
- Boston, MA87 studies
- St. Louis, MO68 studies
- Baltimore, MD60 studies
- San Antonio, TX60 studies
- Chicago, IL59 studies
- Columbus, OH57 studies
- Seattle, WA55 studies
Other studies in Durham
- Breast Cancer63 studies
- Cancer (all types)61 studies
- Multiple Myeloma36 studies
- Acute Myeloid Leukemia34 studies
- Lung Cancer33 studies
- Metastatic Cancer33 studies
- Prostate Cancer32 studies
- Colorectal Cancer30 studies
- Ovarian Cancer28 studies
- Chronic Lymphocytic Leukemia28 studies
- Heart Failure25 studies
- Pancreatic Cancer24 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.